Krystal Biotech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRYS research report →
Companywww.krystalbio.com
Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.
- CEO
- Krish S. Krishnan
- IPO
- 2017
- Employees
- 275
- HQ
- Pittsburgh, PA, US
Price Chart
Valuation
- Market Cap
- $8.90B
- P/E
- 39.31
- P/S
- 21.34
- P/B
- 6.93
- EV/EBITDA
- 45.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 92.79%
- Op Margin
- 42.85%
- Net Margin
- 53.92%
- ROE
- 19.25%
- ROIC
- 13.85%
Growth & Income
- Revenue
- $389.13M · 33.94%
- Net Income
- $204.83M · 129.74%
- EPS
- $7.08 · 126.92%
- Op Income
- $161.29M
- FCF YoY
- 58.51%
Performance & Tape
- 52W High
- $319.48
- 52W Low
- $122.80
- 50D MA
- $270.19
- 200D MA
- $226.68
- Beta
- 0.49
- Avg Volume
- 287.06K
Get TickerSpark's AI analysis on KRYS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 1, 26 | Goux Laurent Louis Jean | other | 0 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 9,050 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 674 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 7,449 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 2,367 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 4,750 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 2,750 |
| Mar 1, 26 | Goux Laurent Louis Jean | other | 19,000 |
| Mar 1, 26 | Thomas John Charles | other | 0 |
| Mar 1, 26 | Thomas John Charles | other | 9,050 |
Our KRYS Coverage
We haven't published any research on KRYS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KRYS Report →